Gilead Sciences Inc. has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use $(CHMP)$ has adopted a positive opinion under accelerated review for lenacapavir, recommending its use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents at increased risk. If approved by the European Commission later this year, lenacapavir will be marketed in the EU under the trade name Yeytuo®. This development represents a significant step towards introducing a twice-yearly HIV prevention option in Europe. Additionally, a positive opinion was received for the EMA's EU-M4all procedure, which aims to facilitate the drug's availability in low- and lower-middle-income countries. This initiative is part of Gilead's broader global access strategy, designed to expedite regulatory review and expand access to lenacapavir for those most in need.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.